Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Are we there yet?
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
Covid vaccine development could go Omicron-and-on
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
The Covid vaccine battleground gets younger
The FDA has finally confirmed the date of a review of Covid vaccine data in the very young, but has Pfizer/Biontech already won the race?
